LA JOLLA, Calif., Jan. 31 /PRNewswire-FirstCall/ -- Stephen D. Ferrone, CEO and President of Immunosyn Corporation (OTC Bulletin Board: IMYN) has been featured in an exclusive interview with CEOCFO Interviews & News. The interview is posted on http://www.immunosyn.com/news-conferences.html
The interview covers topics including Immunosyn's immediate focus, its future development and its market potential, the shift in the pharmaceutical industry toward biologically-derived drugs, the science behind SF-1019, the role of Argyll Biotechnologies, LLC its strategic partner and largest shareholder, Immunosyn's financial picture, the US and European regulatory approval process as it pertains to SF-1019 trials and milestones for which the public and investors should watch.
"We are pleased to be included with CEOCFO's esteemed collection of companies. This interview offers us the opportunity to present noteworthy announcements to brokers, institutional managers and individual investors as part of our strategic market communication plan," says Stephen D. Ferrone.
About CEOCFO Interviews & News http://ceocfointerviews.com:
CEOCFO Interviews & News is a bi-weekly print online publication, marketing engine featuring publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX, OTC: BB, Pink Sheets) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).
The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.
|SOURCE Immunosyn Corporation|
Copyright©2008 PR Newswire.
All rights reserved